Literature DB >> 8757315

CD4 ligand IL-16 inhibits the mixed lymphocyte reaction.

A C Theodore1, D M Center, J Nicoll, G Fine, H Kornfeld, W W Cruikshank.   

Abstract

CD4 participation in TCR/CD3-associated activation through interaction with the MHC class II Ags results in formation of a CD4-TCR/CD3 complex capable of maximal signal transduction. When CD4 binds to alternative ligands such as HIV-1 gp120 or anti-CD4 Abs, Ag stimulation of TCR/CD3 is markedly inhibited, and an unresponsive state develops. To determine if the natural CD4 ligand interleukin-16 also induces unresponsiveness, we tested the effects of rIL-16 on T cell proliferation in mixed lymphocyte reactions. rIL-16 suppressed T cell proliferation in a dose-dependent manner at concentrations of 10(-11) to 10(-7) M. Inhibition of proliferation was present on days 5 to 9 of the mixed lymphocyte reaction. rIL-16 did not modulate membrane CD4, significantly change basal [3H]thymidine incorporation in resting T lymphocytes, or alter viability. The suppressive effect was specifically blocked by preincubation with neutralizing anti-rIL-16 mAb or with recombinant soluble CD4. While the expression of IL-2R on responder cells was unaffected by rIL-16, the addition of exogenous rIL-2 did not restore T cell responsiveness. The unresponsiveness induced by rIL-16 is distinct from that of other CD4 ligands in that CD4 and IL-2R expression are unaffected. The failure of rIL-2 to restore proliferation suggests that the decrease in T cell responsiveness induced by rIL-16 may result from an interruption in the IL-2R-signaling mechanism. These results may help explain how CD4 delivers both activating and inhibitory signals and provides a rationale for the role of IL-16 in the regulation of immune responses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8757315

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Dendritic cell responses to surface properties of clinical titanium surfaces.

Authors:  Peng Meng Kou; Zvi Schwartz; Barbara D Boyan; Julia E Babensee
Journal:  Acta Biomater       Date:  2010-10-25       Impact factor: 8.947

2.  Regulation of the serine-base exchange enzyme system by CD4: effects of monoclonal antibodies, jacalin, interleukin 16 and the HIV membrane protein gp120.

Authors:  M J Dumaurier; C Pelassy; J P Breittmayer; C Aussel
Journal:  Biochem J       Date:  1998-01-01       Impact factor: 3.857

3.  The CXC chemokine stromal cell-derived factor 1 is not responsible for CD8+ T cell suppression of syncytia-inducing strains of HIV-1.

Authors:  S F Lacey; C B McDanal; R Horuk; M L Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

4.  Molecular cloning, sequence, expression, and processing of the interleukin 16 precursor.

Authors:  M Baier; N Bannert; A Werner; K Lang; R Kurth
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

5.  Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes.

Authors:  N L Mathy; W Scheuer; M Lanzendörfer; K Honold; D Ambrosius; S Norley; R Kurth
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

6.  Recombinant interleukin-16 selectively modulates surface receptor expression and cytokine release in macrophages and dendritic cells.

Authors:  E Hermann; E Darcissac; T Idziorek; A Capron; G M Bahr
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

7.  Inhibitory effect of interleukin-16 on interleukin-2 production by CD4+ T cells.

Authors:  H Ogasawara; N Takeda-Hirokawa; I Sekigawa; H Hashimoto; Y Kaneko; S Hirose
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

Review 8.  Inhibitory CD8+ T cells in autoimmune disease.

Authors:  Masakatsu Suzuki; Christine Konya; Jörg J Goronzy; Cornelia M Weyand
Journal:  Hum Immunol       Date:  2008-09-21       Impact factor: 2.850

9.  Identification of new SLE-associated genes with a two-step Bayesian study design.

Authors:  D L Armstrong; A Reiff; B L Myones; F P Quismorio; M Klein-Gitelman; D McCurdy; L Wagner-Weiner; E Silverman; J O Ojwang; K M Kaufman; J A Kelly; J T Merrill; J B Harley; S-C Bae; T J Vyse; G S Gilkeson; P M Gaffney; K L Moser; C Putterman; J C Edberg; E E Brown; J Ziegler; C D Langefeld; R Zidovetzki; C O Jacob
Journal:  Genes Immun       Date:  2009-05-14       Impact factor: 2.676

10.  IL-16 in the airways of lung allograft recipients with acute rejection or obliterative bronchiolitis.

Authors:  M Laan; A Lindén; G C Riise
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.